Eli Lilly and Co (NYSE:LLY) on Tuesday released vials containing low doses of its weight-loss drug Zepbound.

Zepbound (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.

Patients need to use a syringe and needle to draw up the medicine from the vial, which differs from single-dose autoinjector pens, which patients can directly inject under their skin by clicking a button.

The single-dose vials are priced at a 50% or more significant discount compared to the list price of all other incretin (GLP-1) medicines for obesity.

Also Read: Obesity Drugs On Amazon – Eli Lilly Partners With Amazon’s Pharmacy Unit To Deliver Drug ...